MicroRNA-31 inhibits lung adenocarcinoma stem-like cells via down-regulation of MET-pi3k-Akt signaling pathway

Anti-Cancer Agents in Medicinal Chemistry

Volumn 16, Issue 4, 2016, Pages 501-518

  Hou, Chunying ^a   Sun, Bo ^a   Jiang, Yao ^a   Zheng, Ji ^a   Yang, Nan ^a   Ji, Chao ^a   Liang, Zhen ^a   Shi, Jiaojiao ^a   Zhang, Rui ^a   Liu, Yanyong ^a   Ye, Caiying ^a   Zuo, Pingping ^a  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

Author keywords

Cancer stem cells (CSCs); MET; MicroRNA 31 (miR 31); Non small cell lung cancer (NSCLC); PI3K Akt signaling pathway

Indexed keywords

MICRORNA 31; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SCATTER FACTOR RECEPTOR; MICRORNA; MIRN31 MICRORNA, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARCINOGENICITY; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; FLOW CYTOMETRY; GENE OVEREXPRESSION; GENE SEQUENCE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LUCIFERASE ASSAY; LUNG ADENOCARCINOMA; MALE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR VOLUME; UPREGULATION; WESTERN BLOTTING; ADENOCARCINOMA; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; CANCER STEM CELL; CELL CULTURE; DEFICIENCY; DRUG SCREENING; GENETICS; HEK293 CELL LINE; LUNG TUMOR; METABOLISM; NEOPLASMS, EXPERIMENTAL; NUDE MOUSE; PATHOLOGY;

ADENOCARCINOMA; ANIMALS; APOPTOSIS; CELL PROLIFERATION; CELLS, CULTURED; DOWN-REGULATION; DRUG SCREENING ASSAYS, ANTITUMOR; HEK293 CELLS; HUMANS; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MICRORNAS; NEOPLASMS, EXPERIMENTAL; NEOPLASTIC STEM CELLS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-MET; SIGNAL TRANSDUCTION;

EID: 84961659714     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/1871520615666150824152353     Document Type: Article

References (49)

1. Pore, M.M.; Hiltermann, T.J.N.; Kruyt, F.A.E. Targeting Apoptosis Pathways in Lung Cancer. Cancer Lett., 2013, 332(2), 359-368.
2. Johnson, D.H.; Schiller, J.H.; Bunn, P.A. Recent Clinical Advances in Lung Cancer Management. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol., 2014, 32(10), 973-982.
3. Saintigny, P.; Burger, J.A., Recent advances in non-small cell lung cancer biology and clinical management. Discov. Med., 2012, 13(71), 287-297.
4. Jemal, A.; Siegel, R.; Xu, J.; Ward, E. Cancer Statistics, 2010. CA. Cancer J. Clin., 2010, 60(5), 277-300.
5. Kelsey, C.R.; Marks, L.B.; Hollis, D.; Hubbs, J.L.; Ready, N.E.; D’Amico, T.A.; Boyd, J.A. Local Recurrence after Surgery for Early Stage Lung Cancer: An 11-Year experience with 975 patients. Cancer, 2009, 115(22), 5218-5227.
6. Katayama, R.; Shaw, A.T.; Khan, T.M.; Mino-Kenudson, M.; Solomon, B.J.; Halmos, B.; Jessop, N.A.; Wain, J.C.; Yeo, A.T.; Benes, C.; Drew, L.; Saeh, J.C.; Crosby, K.; Sequist, L.V.; Iafrate, A.J.; Engelman, J.A. Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers. Sci. Transl. Med., 2012, 4(120), 120ra17.
7. Steeg, P.S.; Camphausen, K.A.; Smith, Q.R., Brain metastases as preventive and therapeutic targets. Nat. Rev. Cancer, 2011, 11(5), 352-363.
8. Lee, H.W.; Lee, J.I.; Lee, S.J.; Cho, H.J.; Song, H.J.; Jeong, D.E.; Seo, Y.J.; Shin, S.; Joung, J.G.; Kwon, Y.J.; Choi, Y.L.; Park, W.Y.; Lee, H.M.; Seol, H.J.; Shim, Y.M.; Joo, K.M.; Nam, D.H. Patient-derived xenografts from non-small cell lung cancer brain metastases are valuable translational platforms for the development of personalized targeted therapy. Clin. Cancer Res., 2015, 21(15), 1172-1182.
9. Alamgeer, M.; Peacock, C.D.; Matsui, W.; Ganju, V.; Watkins, D.N. Cancer stem cells in lung cancer: Evidence and controversies. Respirol. Carlton Vic., 2013, 18(5), 757-764.
10. Cheng, X.; Chen, H., Tumor heterogeneity and resistance to egfrtargeted therapy in advanced nonsmall cell lung cancer: Challenges and Perspectives. Onco.Targ. Ther., 2014, 7, 1689-1704.
11. Reya, T.; Morrison, S.J.; Clarke, M.F.; Weissman, I.L. Stem Cells, Cancer and Cancer Stem Cells. Nature, 2001, 414(6859), 105-111.
12. Markman, J.L.; Rekechenetskiy, A.; Holler, E.; Ljubimova, J.Y. Nanomedicine therapeutic approaches to overcome cancer drug resistance. Adv. Drug Deliv. Rev., 2013, 65(13-14), 1866-1879.
13. Wang, P.; Suo, Z.; Wang, M.; Høifødt, H.K.; Fodstad, O.; Gaudernack, G.; Kvalheim, G., In Vitro and in Vivo Properties of CD133 expressing cells from human lung cancer cell lines. Exp. Hematol. Oncol., 2013, 2(1), 16.
14. Qu, H.; Li, R.; Liu, Z.; Zhang, J.; Luo, R. Prognostic value of cancer stem cell marker cd133 expression in non-small cell lung cancer: a systematic review. Int. J. Clin. Exp. Pathol., 2013, 6(11), 2644-2650.
15. Tirino, V.; Camerlingo, R.; Bifulco, K.; Irollo, E.; Montella, R.; Paino, F.; Sessa, G.; Carriero, M.V.; Normanno, N.; Rocco, G.; Pirozzi, G. TGF-ß1 exposure induces epithelial to mesenchymal transition both in CSCs and Non-CSCs of the A549 cell line, leading to an increase of migration ability in the CD133+ A549 cell fraction. Cell Death Dis., 2013, 4, e620.
16. Tirino, V.; Camerlingo, R.; Franco, R.; Malanga, D.; La Rocca, A.; Viglietto, G.; Rocco, G.; Pirozzi, G. The role of CD133 in the Identification and characterisation of tumour-initiating cells in nonsmall- cell lung cancer. Eur. J. Cardio-Thorac. Surg., 2009, 36(3), 446-453.
17. Zhang, H.; Yang, N.; Sun, B.; Jiang, Y.; Hou, C.; Ji, C.; Zhang, Y.; Liu, Y.; Zuo, P. CD133 positive cells isolated from A549 cell line exhibited high liver metastatic potential. Neoplasma, 2014, 61(2), 153-160.
18. Baumann, M.; Krause, M.; Hill, R. Exploring the role of cancer stem cells in radioresistance. Nat. Rev. Cancer, 2008, 8(7), 545-554.
19. Shackleton, M.; Quintana, E.; Fearon, E.R.; Morrison, S.J. Heterogeneity in Cancer: Cancer stem cells versus clonal evolution. Cell, 2009, 138(5), 822-829.
20. Meacham, C.E.; Morrison, S.J. Tumour heterogeneity and cancer cell plasticity. Nature, 2013, 501(7467), 328-337.
21. Rahimy, E.; Kuo, S.Z.; Ongkeko, W.M., Evaluation of non-coding RNAs as potential targets in head and neck squamous cell carcinoma cancer stem cells. Curr. Drug Target., 2014, 15(13), 124-1260.
22. Rane, J.K.; Scaravilli, M.; Ylipää, A.; Pellacani, D.; Mann, V.M.; Simms, M.S.; Nykter, M.; Collins, A.T.; Visakorpi, T.; Maitland, N.J., MicroRNA expression profile of primary prostate cancer stem cells as a source of biomarkers and therapeutic targets. Eur. Urol., 2015, 67(1), 7-10.
23. Tezcan, G.; Tunca, B.; Bekar, A.; Budak, F.; Sahin, S.; Cecener, G.; Egeli, U.; Taskapilioglu, M.O.; Kocaeli, H.; Tolunay, S.; Malyer, H.; Demir, C.; Tumen, G. Olea europaea leaf extract improves the treatment response of GBM stem cells by modulating miRNA expression. Am. J. Cancer Res., 2014, 4(5), 572-590.
24. Calin, G.A.; Sevignani, C.; Dumitru, C.D.; Hyslop, T.; Noch, E.; Yendamuri, S.; Shimizu, M.; Rattan, S.; Bullrich, F.; Negrini, M.; Croce, C.M., Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc. Natl. Acad. Sci. USA, 2004, 101(9), 2999-3004.
25. Zhao, Z.G.; Jin, J.Y.; Zhang, A.M.; Zhang, L.P.; Wang, X.X.; Sun, J.G.; Chen, Z.T. MicroRNA Profile of tumorigenic cells during carcinogenesis of lung adenocarcinoma. J. Cell. Biochem., 2015, 116(3), 458-466.
26. Li, J.; Li, P.; Chen, T.; Gao, G.; Chen, X.; Du, Y.; Zhang, R.; Yang, R.; Zhao, W.; Dun, S.; Gao, F.; Zhang, G., Expression of microRNA-96 and its potential functions by targeting FOXO3 in non-small cell lung cancer. Tumour Biol. J. Int. Soc. Oncodevelopmental Biol. Med., 2015, 36(2), 685-692.
27. Wang, F.; Chan, L.W.C.; Law, H.K.W.; Cho, W.C.S.; Tang, P.; Yu, J.; Shyu, C.-R.; Wong, S.C.C.; Yip, S.P.; Yung, B.Y.M. Exploring microRNA-mediated alteration of egfr signaling pathway in non-small cell lung cancer using an mrna:mirna regression model supported by target prediction databases. Genomics, 2014, 104(6 Pt B), 504-511.
28. Zhang, J.-G.; Guo, J.-F.; Liu, D.-L.; Liu, Q.; Wang, J.-J. MicroRNA-101 Exerts tumor-suppressive functions in non-small cell lung cancer through directly targeting enhancer of zeste homolog 2. J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer, 2011, 6(4), 671-678.
29. Wang, R.; Wang, Z.-X.; Yang, J.-S.; Pan, X.; De, W.; Chen, L.-B. MicroRNA-451 functions as a tumor suppressor in human nonsmall cell lung cancer by targeting ras-related protein 14 (RAB14). Oncogene, 2011, 30(23), 2644-2658.
30. Laurila, E.M.; Kallioniemi, A. The diverse role of mir-31 in regulating cancer associated phenotypes. Genes. Chromosomes Cancer, 2013, 52(12), 1103-1113.
31. Lin, P.-C.; Chiu, Y.-L.; Banerjee, S.; Park, K.; Mosquera, J.M.; Giannopoulou, E.; Alves, P.; Tewari, A.K.; Gerstein, M.B.; Beltran, H.; Melnick, A.M.; Elemento, O.; Demichelis, F.; Rubin, M.A. Epigenetic repression of mir-31 disrupts androgen receptor homeostasis and contributes to prostate cancer progression. Cancer Res., 2013, 73(3), 1232-1244.
32. Asangani, I.A.; Harms, P.W.; Dodson, L.; Pandhi, M.; Kunju, L.P.; Maher, C.A.; Fullen, D.R.; Johnson, T.M.; Giordano, T.J.; Palanisamy, N.; Chinnaiyan, A.M. Genetic and epigenetic loss of microRNA-31 leads to feed-forward expression of EZH2 in melanoma. Oncotarget, 2012, 3(9), 1011-1025.
33. Aprelikova, O.; Yu, X.; Palla, J.; Wei, B.-R.; John, S.; Yi, M.; Stephens, R.; Simpson, R.M.; Risinger, J.I.; Jazaeri, A.; Niederhuber, J. The Role of miR-31 and its target gene SATB2 in cancerassociated fibroblasts. Cell Cycle, 2010, 9(21), 4387-4398.
34. Wang, S.; Hu, J.; Zhang, D.; Li, J.; Fei, Q.; Sun, Y. Prognostic Role of microRNA-31 in Various Cancers: A Meta-Analysis. Tumour Biol. J. Int. Soc. Oncodevelopmental Biol. Med., 2014, 35 (11), 11639-11645.
35. Sun, D.; Yu, F.; Ma, Y.; Zhao, R.; Chen, X.; Zhu, J.; Zhang, C.-Y.; Chen, J.; Zhang, J. MicroRNA-31 activates the RAS pathway and functions as an oncogenic MicroRNA in human colorectal cancer by repressing RAS p21 GTPase activating protein 1 (RASA1). J. Biol. Chem., 2013, 288(13), 9508-9518.
36. Liu, X.; Sempere, L.F.; Ouyang, H.; Memoli, V.A.; Andrew, A.S.; Luo, Y.; Demidenko, E.; Korc, M.; Shi, W.; Preis, M.; Dragnev, K.H.; Li, H.; DiRenzo, J.; Bak, M.; Freemantle, S.J.; Kauppinen, S.; Dmitrovsky, E. MicroRNA-31 Functions as an oncogenic microrna in mouse and human lung cancer cells by repressing specific tumor suppressors. J. Clin. Invest., 2010, 120(4), 1298-1309.
37. Okudela, K.; Tateishi, Y.; Umeda, S.; Mitsui, H.; Suzuki, T.; Saito, Y.; Woo, T.; Tajiri, M.; Masuda, M.; Miyagi, Y.; Ohashi, K. Allelic imbalance in the miR-31 host gene locus in lung cancer - its potential role in carcinogenesis. PLoS ONE, 2014, 9(6), e100581.
38. Gao, C.F.; Vande Woude, G.F. HGF/SF-Met Signaling in Tumor Progression. Cell Res., 2005, 15(1), 49-51.
39. Go, H.; Jeon, Y.K.; Park, H.J.; Sung, S.-W.; Seo, J.-W.; Chung, D.H. High MET gene copy number leads to shorter survival in patients with non-small cell lung cancer. J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer, 2010, 5(3), 305-313.
40. Trusolino, L.; Bertotti, A.; Comoglio, P.M., MET Signalling: Principles and functions in development, Organ regeneration and cancer. Nat. Rev. Mol. Cell Biol., 2010, 11(12), 834-848.
41. Cheng, T.-L.; Chang, M.-Y.; Huang, S.-Y.; Sheu, C.-C.; Kao, E.- L.; Cheng, Y.-J.; Chong, I.-W. Overexpression of Circulating c- Met messenger RNA is significantly correlated with nodal stage and early recurrence in non-small cell lung cancer. Chest, 2005, 128(3), 1453-1460.
42. Agwa, E.S.; Ma, P.C. Targeting the MET receptor tyrosine kinase in non-small cell lung cancer: Emerging role of tivantinib. Cancer Manag. Res., 2014, 6, 397-404.
43. Kawakami, H.; Okamoto, I.; Arao, T.; Okamoto, W.; Matsumoto, K.; Taniguchi, H.; Kuwata, K.; Yamaguchi, H.; Nishio, K.; Nakagawa, K.; Yamada, Y. MET amplification as a potential therapeutic target in gastric cancer. Oncotarget, 2012, 4(1), 9-17.
44. Kato, H.; Arao, T.; Matsumoto, K.; Fujita, Y.; Kimura, H.; Hayashi, H.; Nishiki, K.; Iwama, M.; Shiraishi, O.; Yasuda, A.; Shinkai, M.; Imano, M.; Imamoto, H.; Yasuda, T.; Okuno, K.; Shiozaki, H.; Nishio, K., Gene Amplification of EGFR, HER2, FGFR2 and MET in esophageal squamous cell carcinoma. Int. J. Oncol., 2013, 42(4), 1151-1158.
45. Neklason, D.W.; Done, M.W.; Sargent, N.R.; Schwartz, A.G.; Anton-Culver, H.; Griffin, C.A.; Ahnen, D.J.; Schildkraut, J.M.; Tomlinson, G.E.; Strong, L.C.; Miller, A.R.; Stopfer, J.E.; Burt, R.W. Activating mutation in MET oncogene in familial colorectal cancer. BMC Cancer, 2011, 11, 424.
46. Beau-Faller, M.; Ruppert, A.-M.; Voegeli, A.-C.; Neuville, A.; Meyer, N.; Guerin, E.; Legrain, M. MET gene copy number in nonsmall cell lung cancer: Molecular analysis in a targeted tyrosine kinase inhibitor naïve cohort. J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer, 2008, 3(4), 331-339.
47. Mitamura, T.; Watari, H.; Wang, L.; Kanno, H.; Hassan, M.K.; Miyazaki, M.; Katoh, Y.; Kimura, T.; Tanino, M.; Nishihara, H.; Tanaka, S.; Sakuragi, N. Downregulation of miRNA-31 induces taxane resistance in ovarian cancer cells through increase of receptor tyrosine kinase MET. Oncogenesis, 2013, 2(3), e40.
48. Lee, Y.Y.; Kim, H.-P.; Kang, M.J.; Cho, B.-K.; Han, S.-W.; Kim, T.-Y.; Yi, E.C., Phosphoproteomic analysis identifies activated MET-Axis PI3K/AKT and MAPK/ERK in lapatinib-resistant cancer cell line. Exp. Mol. Med., 2013, 45(11), e64.
49. Chang, F.; Lee, J.T.; Navolanic, P.M.; Steelman, L.S.; Shelton, J.G.; Blalock, W.L.; Franklin, R.A.; McCubrey, J.A., Involvement of PI3K/Akt Pathway in cell cycle progression, Apoptosis, and neoplastic transformation: A target for cancer chemotherapy. Leukemia, 2003, 17(3), 590-603.